Medical recognition for PSSD is crucial for getting the resources needed to look for potential treatments. Therefore, the news of the EMA recognizing PSSD is MASSIVE for PSSD sufferers and gives potential SSRI users the choice to be informed about their medication decisions.
This result would not have happened without months of diligent work from many members from the PSSD community.
The official release can be found below:
3. Serotonin and noradrenaline reuptake inhibitors (SNRI)2; selective serotonin reuptake inhibitors (SSRI)3 4 – Persistent sexual dysfunction after drug withdrawal (EPITT no 19277)
Summary of product characteristics
4.4. Special warnings and precautions for use Sexual dysfunction
Selective serotonin reuptake inhibitors (SSRIs)/serotonin norepinephrine reuptake inhibitors (SNRIs) may cause symptoms of sexual dysfunction (see section 4.8). There have been reports of long-lasting sexual dysfunction where the symptoms have continued despite discontinuation of SSRIs/SNRI.
European Medicines Agency, 2019
The original EMA report can be found here.
PSSD LAB 